top of page
Plant Allergen.png

Michael J. Dochniak (Alleamit, Co-founder)

Mr. Dochniak is a University of Wisconsin, River Falls graduate. Michael was a senior chemist/patent coordinator at the H.B. Fuller Company and is an inventor of fifteen (15) U.S. patents.

Born from the creative expression of patents, Michael has authored books on the impact of intellectual property on Artificial Intelligence, Alzheimer’s Disease, Autism Spectrum Disorders, and Climate Change. Additionally, he has documented healthcare worker efforts in the book “Missionary Sheroes of the 19th to 21st Centuries.”

 

In cancer research, Michael’s passion is to discover novel ways that the body’s natural immune system can fight cancer. Alleamit’s core value is to push the boundaries of adaptive immunity and assault the immune tolerance of malignant tumors.

 

Our cancer research mission is to evaluate the validity of the null hypothesis that states, “forced atopy does not inhibit metastatic cancer.” Michael believes that allergies can be natural cancer immunotherapy and has several open-access publications describing the untapped power of allergenic skin creams and allergenic vaccines as cancer immunotherapy.

Allergens.jpg

Immunostimulation

Cancer can be deadly when the immune system is weak or inefficient, resulting in solid tumors that metastasize. An active and robust immune system is the body’s natural defense. Alleamit’s skin cream technology activates the body’s adaptive immune system to disrupt the solid-tumor microenvironment. The mechanism of action encompasses cross-reactivity, immune metabolic interference, and targeted degranulation.

 

Can an expanded immune system starve out solid tumors? Harnessing the natural power of the immune system requires science-based nutrition. At Alleamit, managing essential fatty acids, proteins, carbohydrates, vitamins, minerals, and hydration supports our unique cancer immunotherapy.

Pioneering

Alleamit is a micro-entity organization in Minnesota, USA. Our patented skin cream explores activating adaptive immunity to inhibit metastasis. Cancer therapy is unoccupied with “allergenic” skin cream products. Alleamit’s approach explores pioneering skin creams as an immuno-stimulant. Natural ingredients, ease of manufacture, user-friendly application, and antibody-generating characteristics combine to make it a revolutionary immuno-therapeutic.​

At Alleamit, we recognize that controlled allergies formed by our skin cream are a relative contraindication in that the risks of complications from allergies often do not outweigh the life-threatening situation of a tumor(s) growing out of control and metastasizing.

Cancer Therapy

Skin Cream technology
Scientific consensus asserts that allergies are a maladaptive immune response. At Alleamit, this much-maligned immune response is under investigation to inhibit cancer. Our patented skin cream uses specific allergens to activate the body's natural immune system to disrupt the cancer microenvironment.  The vision is to create cancer therapy that is inherent and patient-friendly.

Humoral Immunotherapy

Skin Cream Technology

Viral infections are a natural and inevitable part of life. In healthy individuals, mortality increases when the body’s innate immune system quickly activates, creating a cytokine storm. A rapid and excessive release of cytokines into the bloodstream can cause acute respiratory distress syndrome and death. Allergies have a stabilizing effect on the immune system during acute infections. At Alleamit, our skin cream therapy is designed to collaborate with innate immunity to reduce the clinical impact of a cytokine storm.

Publications

Allergies are nature's immunotherapy, this mechanism of evolution is embraced and safely magnified with Alleamit’s skin cream technology.

Alleamit 

Skin Cream
Engender natural immunity to fight life-threatening diseases

News

News

 

Press Release

Skin cream to fight metastatic cancer.

 

August 2023 - Alleamit, Inc. enters into an agreement with Marquee Equity to invite global financing entities for initial FDA clinical phases. 

March 2023Minnesota, United States of America, 2023 -- Alleamit, Inc. (Alleamit), is focused on novel skin cream immunotherapeutic; received a Notice of Allowance for the patent application titled Topical Hyper-allergenic Composition And Method Of Treating Using The Same (U.S. Patent Application # 16/513,334). The Notice of Allowance concludes a thorough examination of the skin cream application to become a U.S. patent. 

 

Ever wonder why allergies exist? The immune system is trying to protect you from harm. At Alleamit, research, and development leverage allergies to disrupt and attack the spread of cancer. Our skin cream stimulates the body’s immune response to fight tumors through cross-reactivity, immune metabolic interference, and targeted degranulation. If confirmed in clinical trials, the ability to harness the body’s natural immune system could bring significant cost benefits to patients. Michael J. Dochniak (co-founder) writes that our skin creams encompass pharmaceutical-grade components and FDA-approved allergenics. The technology has the potential to address an unmet medical need in oncology, improve the lives of patients, and bring significant value to shareholders.

 

Goals

The strategy is to deliver superior growth and shareholder return by bringing novel skin cream products to market through global partnering and commercialization efforts.

 

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements on our current expectations and projections about future events and financial trends affecting the financial condition of our business. Forward-looking statements include our expectations regarding pending litigation and other matters. These forward-looking statements are subject to some risks, uncertainties, and assumptions, including, among other things: our history of operating losses and future profit variability; the outcome of any pending litigation; our ability to complete research and further development of our skin cream candidates; the timing, cost, and uncertainty of obtaining regulatory approvals for our skin cream candidates; our ability to commercialize our skin cream candidates; dependence on royalties and grant revenue; our ability to implement our growth strategy; anticipate trends in our business; our limited product line and distribution channels; advances in technologies and development of new competitive products; and our ability to maintain effective internal control over financial reporting. Investors can consider statements that include the words: to; may; could; future; expectations; anticipate; projections; and similar expressions, as well as the negatives of those words or other comparable words, to be uncertain forward-looking statements. Placing undue reliance on any forward-looking statements could turn out to be incorrect. We undertake no obligation to update publicly or revise any forward-looking statements, whether because of new information, future events, or after the date of this report. Forward-looking events and circumstances discussed in this report may not occur; results could differ materially from those anticipated or implied in the forward-looking statements.

About

Team

Investors

Investors

Alleamit welcomes investors

Our strategic goals include broadening U.S. patent protection, procurement of evidence-based research, FDA approval, and negotiating licensing for worldwide distribution.

Alleamit’s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the company’s pipeline through global partnering and commercialization efforts.

Our skin creams have the potential to address a large unmet medical need, improve the lives of a great number of individuals, and bring significant value to Alleamit’s shareholders.

For more information on how to invest, please contact:
Marquee Equity

Investor Relations Contact

Phone: (213) 600-7272
https://marquee-equity.com/

 

bottom of page